Copyright Reports & Markets. All rights reserved.

Global Oral Anti-diabetes Drugs Market Size, Status and Forecast 2021-2027

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Oral Anti-diabetes Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
    • 1.2.2 Liquid
    • 1.2.3 Capsule
    • 1.2.4 Tablet
  • 1.3 Market by Application
    • 1.3.1 Global Oral Anti-diabetes Drugs Market Share by Distribution Channel: 2016 VS 2021 VS 2027
    • 1.3.2 Hospital Pharmacies
    • 1.3.3 Retail Pharmacies
    • 1.3.4 Online Pharmacies
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Oral Anti-diabetes Drugs Market Perspective (2016-2027)
  • 2.2 Oral Anti-diabetes Drugs Growth Trends by Regions
    • 2.2.1 Oral Anti-diabetes Drugs Market Size by Regions: 2016 VS 2021 VS 2027
    • 2.2.2 Oral Anti-diabetes Drugs Historic Market Share by Regions (2016-2021)
    • 2.2.3 Oral Anti-diabetes Drugs Forecasted Market Size by Regions (2022-2027)
  • 2.3 Oral Anti-diabetes Drugs Industry Dynamic
    • 2.3.1 Oral Anti-diabetes Drugs Market Trends
    • 2.3.2 Oral Anti-diabetes Drugs Market Drivers
    • 2.3.3 Oral Anti-diabetes Drugs Market Challenges
    • 2.3.4 Oral Anti-diabetes Drugs Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Oral Anti-diabetes Drugs Players by Revenue
    • 3.1.1 Global Top Oral Anti-diabetes Drugs Players by Revenue (2016-2021)
    • 3.1.2 Global Oral Anti-diabetes Drugs Revenue Market Share by Players (2016-2021)
  • 3.2 Global Oral Anti-diabetes Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Oral Anti-diabetes Drugs Revenue
  • 3.4 Global Oral Anti-diabetes Drugs Market Concentration Ratio
    • 3.4.1 Global Oral Anti-diabetes Drugs Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Oral Anti-diabetes Drugs Revenue in 2020
  • 3.5 Oral Anti-diabetes Drugs Key Players Head office and Area Served
  • 3.6 Key Players Oral Anti-diabetes Drugs Product Solution and Service
  • 3.7 Date of Enter into Oral Anti-diabetes Drugs Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Oral Anti-diabetes Drugs Breakdown Data by Type

  • 4.1 Global Oral Anti-diabetes Drugs Historic Market Size by Type (2016-2021)
  • 4.2 Global Oral Anti-diabetes Drugs Forecasted Market Size by Type (2022-2027)

5 Oral Anti-diabetes Drugs Breakdown Data by Distribution Channel

  • 5.1 Global Oral Anti-diabetes Drugs Historic Market Size by Distribution Channel (2016-2021)
  • 5.2 Global Oral Anti-diabetes Drugs Forecasted Market Size by Distribution Channel (2022-2027)

6 North America

  • 6.1 North America Oral Anti-diabetes Drugs Market Size (2016-2027)
  • 6.2 North America Oral Anti-diabetes Drugs Market Size by Type
    • 6.2.1 North America Oral Anti-diabetes Drugs Market Size by Type (2016-2021)
    • 6.2.2 North America Oral Anti-diabetes Drugs Market Size by Type (2022-2027)
    • 6.2.3 North America Oral Anti-diabetes Drugs Market Size by Type (2016-2027)
  • 6.3 North America Oral Anti-diabetes Drugs Market Size by Distribution Channel
    • 6.3.1 North America Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2021)
    • 6.3.2 North America Oral Anti-diabetes Drugs Market Size by Distribution Channel (2022-2027)
    • 6.3.3 North America Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2027)
  • 6.4 North America Oral Anti-diabetes Drugs Market Size by Country
    • 6.4.1 North America Oral Anti-diabetes Drugs Market Size by Country (2016-2021)
    • 6.4.2 North America Oral Anti-diabetes Drugs Market Size by Country (2022-2027)
    • 6.4.3 United States
    • 6.4.4 Canada

7 Europe

  • 7.1 Europe Oral Anti-diabetes Drugs Market Size (2016-2027)
  • 7.2 Europe Oral Anti-diabetes Drugs Market Size by Type
    • 7.2.1 Europe Oral Anti-diabetes Drugs Market Size by Type (2016-2021)
    • 7.2.2 Europe Oral Anti-diabetes Drugs Market Size by Type (2022-2027)
    • 7.2.3 Europe Oral Anti-diabetes Drugs Market Size by Type (2016-2027)
  • 7.3 Europe Oral Anti-diabetes Drugs Market Size by Distribution Channel
    • 7.3.1 Europe Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2021)
    • 7.3.2 Europe Oral Anti-diabetes Drugs Market Size by Distribution Channel (2022-2027)
    • 7.3.3 Europe Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2027)
  • 7.4 Europe Oral Anti-diabetes Drugs Market Size by Country
    • 7.4.1 Europe Oral Anti-diabetes Drugs Market Size by Country (2016-2021)
    • 7.4.2 Europe Oral Anti-diabetes Drugs Market Size by Country (2022-2027)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Oral Anti-diabetes Drugs Market Size (2016-2027)
  • 8.2 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Type
    • 8.2.1 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Type (2016-2021)
    • 8.2.2 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Type (2022-2027)
    • 8.2.3 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Type (2016-2027)
  • 8.3 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Distribution Channel
    • 8.3.1 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2021)
    • 8.3.2 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Distribution Channel (2022-2027)
    • 8.3.3 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2027)
  • 8.4 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region
    • 8.4.1 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region (2016-2021)
    • 8.4.2 Asia-Pacific Oral Anti-diabetes Drugs Market Size by Region (2022-2027)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Oral Anti-diabetes Drugs Market Size (2016-2027)
  • 9.2 Latin America Oral Anti-diabetes Drugs Market Size by Type
    • 9.2.1 Latin America Oral Anti-diabetes Drugs Market Size by Type (2016-2021)
    • 9.2.2 Latin America Oral Anti-diabetes Drugs Market Size by Type (2022-2027)
    • 9.2.3 Latin America Oral Anti-diabetes Drugs Market Size by Type (2016-2027)
  • 9.3 Latin America Oral Anti-diabetes Drugs Market Size by Distribution Channel
    • 9.3.1 Latin America Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2021)
    • 9.3.2 Latin America Oral Anti-diabetes Drugs Market Size by Distribution Channel (2022-2027)
    • 9.3.3 Latin America Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2027)
  • 9.4 Latin America Oral Anti-diabetes Drugs Market Size by Country
    • 9.4.1 Latin America Oral Anti-diabetes Drugs Market Size by Country (2016-2021)
    • 9.4.2 Latin America Oral Anti-diabetes Drugs Market Size by Country (2022-2027)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Oral Anti-diabetes Drugs Market Size (2016-2027)
  • 10.2 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Type
    • 10.2.1 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Type (2016-2021)
    • 10.2.2 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Type (2022-2027)
    • 10.2.3 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Type (2016-2027)
  • 10.3 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Distribution Channel
    • 10.3.1 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2021)
    • 10.3.2 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Distribution Channel (2022-2027)
    • 10.3.3 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Distribution Channel (2016-2027)
  • 10.4 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country
    • 10.4.1 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country (2016-2021)
    • 10.4.2 Middle East & Africa Oral Anti-diabetes Drugs Market Size by Country (2022-2027)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 Sanofi
    • 11.1.1 Sanofi Company Details
    • 11.1.2 Sanofi Business Overview
    • 11.1.3 Sanofi Oral Anti-diabetes Drugs Introduction
    • 11.1.4 Sanofi Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
    • 11.1.5 Sanofi Recent Development
  • 11.2 Eli Lilly
    • 11.2.1 Eli Lilly Company Details
    • 11.2.2 Eli Lilly Business Overview
    • 11.2.3 Eli Lilly Oral Anti-diabetes Drugs Introduction
    • 11.2.4 Eli Lilly Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
    • 11.2.5 Eli Lilly Recent Development
  • 11.3 AstraZeneca plc
    • 11.3.1 AstraZeneca plc Company Details
    • 11.3.2 AstraZeneca plc Business Overview
    • 11.3.3 AstraZeneca plc Oral Anti-diabetes Drugs Introduction
    • 11.3.4 AstraZeneca plc Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
    • 11.3.5 AstraZeneca plc Recent Development
  • 11.4 Astellas Pharma Inc
    • 11.4.1 Astellas Pharma Inc Company Details
    • 11.4.2 Astellas Pharma Inc Business Overview
    • 11.4.3 Astellas Pharma Inc Oral Anti-diabetes Drugs Introduction
    • 11.4.4 Astellas Pharma Inc Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
    • 11.4.5 Astellas Pharma Inc Recent Development
  • 11.5 Johnson & Johnson (Janssen Pharmaceuticals)
    • 11.5.1 Johnson & Johnson (Janssen Pharmaceuticals) Company Details
    • 11.5.2 Johnson & Johnson (Janssen Pharmaceuticals) Business Overview
    • 11.5.3 Johnson & Johnson (Janssen Pharmaceuticals) Oral Anti-diabetes Drugs Introduction
    • 11.5.4 Johnson & Johnson (Janssen Pharmaceuticals) Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
    • 11.5.5 Johnson & Johnson (Janssen Pharmaceuticals) Recent Development
  • 11.6 Boehringer Ingelheim
    • 11.6.1 Boehringer Ingelheim Company Details
    • 11.6.2 Boehringer Ingelheim Business Overview
    • 11.6.3 Boehringer Ingelheim Oral Anti-diabetes Drugs Introduction
    • 11.6.4 Boehringer Ingelheim Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
    • 11.6.5 Boehringer Ingelheim Recent Development
  • 11.7 Merck
    • 11.7.1 Merck Company Details
    • 11.7.2 Merck Business Overview
    • 11.7.3 Merck Oral Anti-diabetes Drugs Introduction
    • 11.7.4 Merck Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
    • 11.7.5 Merck Recent Development
  • 11.8 Takeda
    • 11.8.1 Takeda Company Details
    • 11.8.2 Takeda Business Overview
    • 11.8.3 Takeda Oral Anti-diabetes Drugs Introduction
    • 11.8.4 Takeda Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
    • 11.8.5 Takeda Recent Development
  • 11.9 Bristol Myers Squibb
    • 11.9.1 Bristol Myers Squibb Company Details
    • 11.9.2 Bristol Myers Squibb Business Overview
    • 11.9.3 Bristol Myers Squibb Oral Anti-diabetes Drugs Introduction
    • 11.9.4 Bristol Myers Squibb Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
    • 11.9.5 Bristol Myers Squibb Recent Development
  • 11.10 Novartis
    • 11.10.1 Novartis Company Details
    • 11.10.2 Novartis Business Overview
    • 11.10.3 Novartis Oral Anti-diabetes Drugs Introduction
    • 11.10.4 Novartis Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
    • 11.10.5 Novartis Recent Development
  • 11.11 Pfizer
    • 11.11.1 Pfizer Company Details
    • 11.11.2 Pfizer Business Overview
    • 11.11.3 Pfizer Oral Anti-diabetes Drugs Introduction
    • 11.11.4 Pfizer Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
    • 11.11.5 Pfizer Recent Development
  • 11.12 Abbott
    • 11.12.1 Abbott Company Details
    • 11.12.2 Abbott Business Overview
    • 11.12.3 Abbott Oral Anti-diabetes Drugs Introduction
    • 11.12.4 Abbott Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
    • 11.12.5 Abbott Recent Development
  • 11.13 Biocon
    • 11.13.1 Biocon Company Details
    • 11.13.2 Biocon Business Overview
    • 11.13.3 Biocon Oral Anti-diabetes Drugs Introduction
    • 11.13.4 Biocon Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
    • 11.13.5 Biocon Recent Development
  • 11.14 Sunpharma
    • 11.14.1 Sunpharma Company Details
    • 11.14.2 Sunpharma Business Overview
    • 11.14.3 Sunpharma Oral Anti-diabetes Drugs Introduction
    • 11.14.4 Sunpharma Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
    • 11.14.5 Sunpharma Recent Development
  • 11.15 Novo Nordisk
    • 11.15.1 Novo Nordisk Company Details
    • 11.15.2 Novo Nordisk Business Overview
    • 11.15.3 Novo Nordisk Oral Anti-diabetes Drugs Introduction
    • 11.15.4 Novo Nordisk Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
    • 11.15.5 Novo Nordisk Recent Development
  • 11.16 Piramal Healthcare
    • 11.16.1 Piramal Healthcare Company Details
    • 11.16.2 Piramal Healthcare Business Overview
    • 11.16.3 Piramal Healthcare Oral Anti-diabetes Drugs Introduction
    • 11.16.4 Piramal Healthcare Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
    • 11.16.5 Piramal Healthcare Recent Development
  • 11.17 Bayer Healthcare
    • 11.17.1 Bayer Healthcare Company Details
    • 11.17.2 Bayer Healthcare Business Overview
    • 11.17.3 Bayer Healthcare Oral Anti-diabetes Drugs Introduction
    • 11.17.4 Bayer Healthcare Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
    • 11.17.5 Bayer Healthcare Recent Development
  • 11.18 Dr. Reddy’s Laboratories Ltd
    • 11.18.1 Dr. Reddy’s Laboratories Ltd Company Details
    • 11.18.2 Dr. Reddy’s Laboratories Ltd Business Overview
    • 11.18.3 Dr. Reddy’s Laboratories Ltd Oral Anti-diabetes Drugs Introduction
    • 11.18.4 Dr. Reddy’s Laboratories Ltd Revenue in Oral Anti-diabetes Drugs Business (2016-2021)
    • 11.18.5 Dr. Reddy’s Laboratories Ltd Recent Development
  • 11.18 Glenmark Pharmaceuticals Ltd

.1 Glenmark Pharmaceuticals Ltd Company Details

    .2 Glenmark Pharmaceuticals Ltd Business Overview

      .3 Glenmark Pharmaceuticals Ltd Oral Anti-diabetes Drugs Introduction

        .4 Glenmark Pharmaceuticals Ltd Revenue in Oral Anti-diabetes Drugs Business (2016-2021)

          .5 Glenmark Pharmaceuticals Ltd Recent Development

            12 Analyst's Viewpoints/Conclusions

              13 Appendix

              • 13.1 Research Methodology
                • 13.1.1 Methodology/Research Approach
                • 13.1.2 Data Source
              • 13.2 Disclaimer

              Global Oral Anti-diabetes Drugs Scope and Market Size
              Oral Anti-diabetes Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Oral Anti-diabetes Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Distribution Channel in terms of revenue and forecast for the period 2016-2027.

              Segment by Type
              by Type
              Liquid
              Capsule
              Tablet
              by Drug Class
              Sulfonylureas
              Meglitinides
              Biguanides
              Others

              Segment by Distribution Channel
              Hospital Pharmacies
              Retail Pharmacies
              Online Pharmacies

              By Region
              North America
              United States
              Canada
              Europe
              Germany
              France
              U.K.
              Italy
              Russia
              Nordic
              Rest of Europe
              Asia-Pacific
              China
              Japan
              South Korea
              Southeast Asia
              India
              Australia
              Rest of Asia
              Latin America
              Mexico
              Brazil
              Rest of Latin America
              Middle East & Africa
              Turkey
              Saudi Arabia
              UAE
              Rest of MEA

              By Company
              Sanofi
              Eli Lilly
              AstraZeneca plc
              Astellas Pharma Inc
              Johnson & Johnson (Janssen Pharmaceuticals)
              Boehringer Ingelheim
              Merck
              Takeda
              Bristol Myers Squibb
              Novartis
              Pfizer
              Abbott
              Biocon
              Sunpharma
              Novo Nordisk
              Piramal Healthcare
              Bayer Healthcare
              Dr. Reddy’s Laboratories Ltd
              Glenmark Pharmaceuticals Ltd

              Buy now